neuroendocrine%20tumors
NEUROENDOCRINE TUMORS
Neuroendocrine tumors are rare, small, slow-growing epithelial neoplasms with predominant neuroendocrine differentiation found in most organs of the body.
They arise from cells throughout the diffuse endocrine system.
Carcinoid tumors and pancreatic neuroendocrine tumors are the most common.
Carcinoid tumors arise from the lungs & bronchi, stomach, small intestine, appendix, rectum or thymus.
Majority of the neuroendocrine tumors are sporadic but some tumors are caused by inherited genetic syndromes such as multiple endocrine neoplasia, Von-Hippel Lindau disease, tuberous sclerosis complex and neurofibromatosis.
They have the ability to store and secrete various peptides and neuroamines.

Neuroendocrine Tumors References

  1. MedWormhttp://www.medworm.com/rss/index.php/Gastroenterology/17/http://www.medworm.com/rss/medicalfeeds/specialities/Gastroenterology.xml
  2. MedWormhttp://www.medworm.com/rss/index.php/Endocrinology/15/http://www.medworm.com/rss/medicalfeeds/specialities/Endocrinology.xml
  3. MedWormhttp://www.medworm.com/rss/index.php/Cancer-%26-Oncology/6/http://www.medworm.com/rss/medicalfeeds/specialities/Cancer-Oncology.xml
  4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: neuroendocrine tumors. Version 2.2014. NCCN. http://www.nccn.org. Accessed 14 Apr 2014.
  5. Öberg K, Knigge U, Kwekkeboom D, Perren A; ESMO Guidelines Working Group. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012 Oct;23(Suppl 7):vii124-130. http://annonc.oxfordjournals.org/content/23/suppl_7/vii124.full.pdf. Accessed 14 April 2014. PMID: 22997445
  6. Anthony LB, Strosberg JR, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (NETs): well-differentiated NETs of the distal colon and rectum. Pancreas. 2010;39(6):767-774. doi: 10.1097/MPA.0b013e3181ec1261. PMID: 20664474
  7. Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. Endocr Relat Cancer. 2004;11(1):1-18. PMID: 15027882
  8. Boudreaux JP, Klimstra DS, Hassan MM, et al. NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas. 2010;39(6):753-766. doi: 10.1097/MPA.0b013e3181ebb2a5. PMID: 20664473
  9. Kalemkerian GP, Akerley W, Blum MG, et al; National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: small cell lung cancer. NCCN. 2010.
  10. Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39(6):707-712. doi: 10.1097/MPA.0b013e3181ec124e. PMID: 20664470
  11. Kocha W, Maroun J, Kennecke H, et al. Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group. Curr Oncol. 2010;17(3):49-64. PMID: 20567626
  12. Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010;39(6):735-752. doi: 10.1097/MPA.0b013e3181ebb168. PMID: 20664472
  13. Kulke MH, Bergland E, Clark OH, et al; National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: neuroendocrine tumors. NCCN. Mar 2012.
  14. Massironi S, Sciola V, Peracchi M, et al. Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol. 2008 Sep;14(35):5377-5384. PMID: 18803349
  15. Phan AT, Oberg K, Choi J, et al. NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas. 2010;39(6):784-798. doi: 10.1097/MPA.0b013e3181ec1380. PMID: 20664476
  16. Strosberg JR, Coppola D, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010;39(6):799-800. doi: 10.1097/MPA.0b013e3181ebb56f. PMID: 20664477
  17. Vinik AI, Woltering EA, Warner RR, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010;39(6):713-734. doi: 10.1097/MPA.0b013e3181ebaffd. PMID: 20664471
  18. Garcia-Carbonero R, JImenez-Fonseca P, Teulé A, Barriuso J, Sevilla I. SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014. Clin Transl Oncol. 2014 Dec;16(12):1025-1034. http://www.ncbi.nlm.nih.gov. Accessed 05 Jan 2016. PMID: 25183048
  19. Kulke MH, Shah MH, Benson AB 3rd, et al; National Comprehensive Cancer Network. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw. 2015 Jan;13(1):78-108. http://www.nccn.org. Accessed 05 Jan 2016. PMID: 25583772
  20. Kunz PL, Reidy-Lagunes D, Anthony LB, et al; North American Neuroendocrine Tumor Society. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013 May;42(4):557-577. https://www.nanets.net. Accessed 05 Jan 2016. PMID: 23591432
  21. American Cancer Society. Gastrointestinal carcinoid tumor stages. American Cancer Society website. https://www.cancer.org. Dec 2017.
  22. American Cancer Society. Pancreatic neuroendocrine tumor stages. American Cancer Society website. https://www.cancer.org. . Dec 2017.
  23. National Comprehensive Cancer Network. Neuroendocrine and adrenal tumors. Version 2.2018. NCCN. https://www.nccn.org/. May 2018.
  24. Singh S, Asa SL, Dey C, et al. Diagnosis and management of gastrointestinal neuroendocrine tumors: an evidence-based Canadian consensus. Cancer Treat Rev. 2016 Jun;47:32-45. doi: 10.1016/j.ctrv.2016.05.003. PMID: 27236421
  25. National Comprehensive Cancer Network (NCCN). Neuroendocrine and adrenal tumors. Version 1.2019. NCCN. https://www.nccn.org/. Mar 2019.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Updates from the SECURE-IBD* registry reveal that treatment with thiopurine, either alone or in combination with tumour necrosis factor inhibitors (TNFis), for inflammatory bowel disease (IBD) was associated with a greater risk of severe COVID-19 compared with TNFis monotherapy.